Spero therapeutics announces closing of exclusive license agreement with gsk for tebipenem hbr

Pursuant to the agreement, spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of spero common stock, and is eligible for potential future milestone payments and tiered royalties pursuant to the agreement, spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of spero common stock, and is eligible for potential future milestone payments and tiered royalties
SPRO Ratings Summary
SPRO Quant Ranking